Summary
This prediction ended on 04.03.19 with a price of €22.02. With a performance of 6.48%, the BUY prediction by melinda for Evotec SE closed with a slight gain. melinda has 50% into this predictionEvotec is a German-based biotech company that provides drug discovery and development solutions to pharmaceutical and biotechnology companies. The company operates in the fields of neuroscience, immunology, oncology, and infectious diseases, and its services include hit identification, target validation, and preclinical and clinical development. Evotec has partnerships with major pharmaceutical companies and has developed its own pipeline of drugs, with a focus on developing treatments for conditions such as Alzheimer's disease and diabetes. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of approximately €5.5 billion.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Evotec SE | 4.652% | 4.652% | -41.565% | -71.923% |
| iShares Core DAX® | -0.922% | -1.993% | 13.399% | 16.075% |
| iShares Nasdaq 100 | 0.371% | -0.868% | 41.541% | 46.938% |
| iShares Nikkei 225® | 2.224% | -5.187% | 20.497% | 4.643% |
| iShares S&P 500 | -0.026% | -0.918% | 30.410% | 42.418% |
Comments by melinda for this prediction
In the thread Evotec AG diskutieren
SecteurRecherche biotechnologique et médicale Agenda 14/03 Présentation
- développement de systèmes de criblage à haut débit;
- recherche et développement de produits pharmaceutiques: destinés au traitement des maladies neurologiques, oncologiques, inflammatoires et des douleurs;
- autres: the identification of cibles, of development of pharmacy tests, of the geography to high débit, etc. Germany, Germany
(11,9%), States (37.8%) , France (23,4%), Royaume Uni (10,4%) et autres (16,5%).
Nombre d'employés
: 2 178 personnes.